New Delhi: The results of the Phase III trial of Covaxin, an anti-corona virus vaccine, have come to light. The vaccine has been found to be up to 81% effective in the results of the Phase III trial. Bharat Biotech, the company that manufactures covariate, said that these trials were carried out on 25,800 people in the country. Which were the biggest trials ever conducted by ICMR. According to the trial of covicin, this vaccine was found to be 81 percent effective in those who were not infected with Kovid-19.
In order to collect further data and to know the efficacy of the vaccine, clinical trials will continue for final analysis in 130 confirmed cases. Let me tell you that a lot of questions were raised by the opposition about the use of covaxine in the country. The vaccination campaign started in the country from January 16, in which the beneficiaries are being vaccinated with covicin and Covishield.
Earlier in January, a review report of Covaxin was also revealed stating that the Covacine vaccine developed by Bharat Biotech is also effective in protecting against the new form of Corona virus found in Britain. The vaccine was reported in a pre-publication review report by BioRxivs. It is operated by the Cold Spring Harbor Laboratory, non-profit research and educational institution in New York.
The report said that Bharat Biotech performed the Reduction Neutralization Test (PRNT 50) on blood collected from 26 participants taking covaccine. It investigated the new form of virus found in Britain and its effectiveness against other strains.
Covaxine is a fully indigenous vaccine, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
